• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nexalin Technology, Inc. - Warrant (NQ: NXLIW )

    0.1901 UNCHANGED
    Streaming Delayed Price Updated: 3:09 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.1901
    Bid (Size) 0.1223 (1)
    Ask (Size) 0.3200 (1)
    Prev. Close 0.1901
    Today's Range 0.1901 - 0.1901
    52wk Range 0.0075 - 0.5600
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces Closing of $5.2 Million Public Offering
    From Nexalin Technology, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +2434.67%
    +2434.67%
    1 Month
    +5.67%
    +5.67%
    3 Month
    -14.21%
    -14.21%
    6 Month
    +2218.29%
    +2218.29%
    1 Year
    +72.82%
    +72.82%

    More News

    Read More
    Nexalin Technology Announces Pricing of $5.2 Million Public Offering
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
    Via ACCESSWIRE
    Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Unveils Next-Generation HALO™ Clarity
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.